Publications

Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors.

CA McIntyre, V Rudneva, AL Richards, W Park, WR Jarnagin, ...

Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET …

AC Dueck, B Fruth, SM Geyer, T Zemla, S Pulsipher, FS Ou, JD Acoba, ...

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel+ gemcitabine in treatment-naive patients with metastatic pancreatic ductal …

D Melisi, T Macarulla, C De La Fouchardiere, RAP Cid, SR Chandana, ...

Hepatic artery infusional chemotherapy for unresectable intrahepatic cholangiocarcinoma

R Alessandris, M Rousian, L Schleimer, H Kalvin, A Cercek, L Connell, ...

Impact of clinical target volume utilization on outcomes in patients with non-spine bone oligometastases treated with stereotactic ablative radiation therapy

E O’Reilly, E Johal, H Clark, B Mou, RE Cereno, M Liu, D Schellenberg, ...

Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer

Schleimer LE, Aviki E, Kalvin HL, Magnin J, Sokolowski SS, Kingham TP, O'Reilly EM, Varghese AM, et al.

Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3.

M Abdelrahim, G Khan, H Hatoum, A Zervoudakis, F Dayyani, L Zhang, ...

Indian Consensus Guidelines for the Management of Pancreatic Cancer

V Lavingia, S Gohel, S Shrikhande, SK Mullapally, A Ramaswamy, ...

Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma

Judge SJ, Manin E, Chou J, Torphy RJ, McIntyre CA, Balachandran VP, D'Angelica MI, Drebin JA, et al.

International Fibrolamellar Cancer Registry: Opportunities and Challenges

Al Mahmasani L, Capanu M, Losert K, Chou JF, Lowery MA, Hennessy M, Ray M, Chambers S, et al.

Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival

Chandra P, Song Y, Drill E, Wei AC, Kemeny N, Cercek A, Connell L, Harding J, et al.

Longitudinal imaging markers for pancreas cancer tumor response via Eshelby biomechanics

JS Heiselman, N Horvat, M El Homsi, BL Ecker, EM O’Reilly, TP Kingham, ...

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, et al.

Maximal Ablative Irradiation Because of Encasement for Patients with Potentially Resectable Locally Advanced Pancreatic Cancer: Final Results of Phase II MAIBE Trial

M Reyngold, A Wei, C Hajj, M Zinovoy, W Jarnagin, MI D'Angelica, ...

Mitigation of gastrointestinal (GI) side effects among patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma (mPDAC)

P Patel, A Laursen, C Lieb, F Maxwell, E O'Reilly, AM Siney

Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS …

D Cowzer, HS Walch, P Atri, F Shah, R Huq, DN Khalil, W Park, R Yeh, ...

MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors.

NJ Lakhani, D Melisi, V Subbiah, NR Ammakkanavar, EM O'Reilly, ...

Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hypofractionated Offline Adapted Radiation Therapy for Locally Advanced Pancreatic Cancer

Chuong MD, O'Reilly EM, Herrera RA, Zinovoy M, Mittauer KE, Rubens M, Kaiser A, Romesser PB, et al.

NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the …

V Chung, MD Kochenderfer, N Natarajan, GR Williams, AA Laursen, ...

Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma

GK Abou-Alfa, T Meyer, RKG Do, SA Piha-Paul, JS Light, S Sherrin, ...

Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy

Reyngold M, Schoenfeld JD, O'Reilly EM, Varghese AM, White C, Zinovoy M, Romesser PB, Wu AJ, et al.

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in PDAC

AM Schram, SR Yang, M Repetto, R Velasco, G Kahn, R Do, S Dinapoli, ...

Obesity and biliary tract cancers: Changing epidemiology.

L Al Mahmasani, JF Chou, M Capanu, A Srivastava, CS Sigel, ...

OR19-06 Safety and Effectiveness of Sulfonylureas for Pancreas-Cancer Induced Metabolic Dysregulation

JH Flory, H Martirosova, E Tan, M Bakkar, M Goncalves, W Park, ...

Orally administered MOMA-313 as monotherapy or combination therapy in participants with advanced or metastatic solid homologous recombination (HR) deficient tumors: Phase 1 …

A Patnaik, W Abida, KA Reiss, J De Bono, R McKay, AH Bryce, ...

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

Knox JJ, O'Kane G, King D, Laheru D, Habowski AN, Yu K, Perez K, Aguirre AJ, et al.

Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC

AN Habowski, H Patel, C Tsang, L St. Surin, D Plenker, FM Kouassi, ...

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, et al.

Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors

JA Chan, S Geyer, T Zemla, MV Knopp, S Behr, S Pulsipher, FS Ou, ...

Plant-based diet and survival among patients with metastatic colorectal cancer

E Cheng, FS Ou, C Gatten, C Ma, AP Venook, HJ Lenz, EM O’Reilly, ...

Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702.

JA Nowak, Q Shi, T Twombly, LD Pederson, C Ma, JP Vaeyrynen, ...

Prognostic and predictive role of T cell infiltration in stage III colon cancer (CC) treated with celecoxib: CALGB/SWOG 80702

Y Takashima, C Ma, Q Shi, AD Costa, T Twombly, JP Väyrynen, M Zhao, ...

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)

L Dercle, S Geyer, AB Nixon, F Innocenti, Q Shi, SB Jacobson, L Luk, ...

Randomized phase II trial of olaparib+ pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 …

V Chung, KA Guthrie, MJ Pishvaian, AM Lowy, D Sohal, KA Reiss, ...

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, et al.

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer …

FA Sinicrope, FS Ou, D Arnold, W Peters, RJ Behrens, CH Lieu, K Matin, ...

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, …

Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702)(Alliance).

E Cheng, Q Shi, AF Shields, C Kuang, A Shergill, C Ma, KA Guthrie, ...

Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)

Cheng E, Shi Q, Shields AF, Xue X, Rohan TE, Kuang C, Shergill AP, Ma C, et al.

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405 (vol 114, pg 427, 2021)

M Lipsyc-Sharf, S Zhang, FS Ou, C Ma, NJ McCleary, D Niedzwiecki, ...

Survival of patients with resected microsatellite instability-high, mismatch repair deficient, and lynch syndrome-associated pancreatic ductal adenocarcinomas

EL Eikenboom, N Nasar, K Seier, M Gönen, MCW Spaander, EM O’Reilly, ...

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

Blair AB, Radomski SN, Chou J, Liu M, Howell TC, Park W, O'Reilly EM, Zheng L, et al.

Target identification for antibody-drug-conjugate (ADC) therapy in biliary tract cancers (BTC)

A Dhyani, Z Tarcan, J Chou, R Thummalapalli, W Chatila, S Nag, E Rosen, ...

The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions

Hayashi A, Ho YJ, Makohon-Moore AP, Zucker A, Hong J, Umeda S, Karnoub ER, Huang J, et al.

Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS (ON) multi-selective inhibitor, versus standard …

BM Wolpin, ZA Wainberg, I Garrido-Laguna, GA Manji, AI Spira, NS Azad, ...

Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response …

CS Kitchens, Q Shi, A Dasari, J Garcia-Aguilar, HK Sanoff, TJ George, ...

Tu1375: INCIDENCE OF PANCREATIC ADENOCARCINOMA AND NEOPLASTIC PROGRESSION DURING IMAGING SURVEILLANCE IN HIGH-RISK INDIVIDUALS FOR PANCREATIC CANCER

SE Lee, MA Schattner, J Naduparambil, K O’Connell, N Peeri, P Wang, ...

Utilizing Patient Input in Rectal Cancer Trial Design

Alvarez J, Zambare W, George M, Garcia R, Gallagher P, Kitchens C, Bercz A, Kim MJ, et al.

1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including …

J Chan, S Geyer, T Zemla, MV Knopp, SC Behr, S Pulsipher, J Acoba, ...

1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination …

W Park, C O’Connor, J Chou, C Schwartz, M Larsen, A Varghese, K Yu, ...